Engineered Fab' fragment anti-tumor necrosis factor alpha in combination with disease modifying anti-rheumatic drugs

摘要

The present invention provides a combination therapeutic composition useful in modulating, treating and/or preventing inflammatory diseases. The therapeutic composition includes antibody Fab′ fragment CDP870 that is specific for antigenic determinants of tumor necrosis factor alpha and at least one Disease Modifying Anti-Rheumatic Disease drug such as methotrexate or sulfasalazine. The therapeutic composition can be administered to either a human or animal subject in single or multiple doses over time in the treatment of rheumatoid arthritis, Crohn's Disease or any other inflammatory disease.